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Background: Syndecan-1 promotes bacterial infections, but how this is accomplished remains unclear.
Results: Syndecan-1 and 2-O-sulfated heparan compounds specifically enhanced S. aureus corneal virulence and inhibited
bacterial killing by CRAMP secreted from degranulated neutrophils.
Conclusion: Specific structural motifs in syndecan-1 HS promote S. aureus corneal infection by inhibiting neutrophil CRAMP.
Significance: This study uncovers a new pathogenic role for syndecan-1 in bacterial infection.
Ablation of syndecan-1 in mice is a gain of function mutation
that enables mice to significantly resist infection by several bac-
terial pathogens. Syndecan-1 shedding is induced by bacterial
virulence factors, and inhibition of shedding attenuates bacte-
rial virulence, whereas administration of purified syndecan-1
ectodomain enhances virulence, suggesting that bacteria sub-
vert syndecan-1 ectodomains released by shedding for their
pathogenesis. However, the pro-pathogenic functions of synde-
can-1 ectodomain have yet to be clearly defined. Here, we exam-
ined how syndecan-1 ectodomain enhances Staphylococcus
aureus virulence in injured mouse corneas. We found that syn-
decan-1 ectodomain promotes S. aureus corneal infection in an
HS-dependent manner. Surprisingly, we found that this pro-
pathogenic activity is dependent on 2-O-sulfated domains in
HS, indicating that the effects of syndecan-1 ectodomain are
structure-based. Our results also showed that purified synde-
can-1 ectodomain and heparan compounds containing 2-O-sul-
fate motifs inhibit S. aureus killing by antimicrobial factors
secreted by degranulated neutrophils, but does not affect intra-
cellular phagocytic killing by neutrophils. Immunodepletion of
antimicrobial factors with staphylocidal activities demonstrated
that CRAMP, a cationic antimicrobial peptide, is primarily
responsible for S. aureus killing among other factors secreted by
degranulated neutrophils. Furthermore, we found that purified
syndecan-1 ectodomain and heparan compounds containing
2-O-sulfate units potently and specifically inhibit S. aureus kill-
ing by synthetic CRAMP. These results provide compelling evi-
dence that a specific subclass of sulfate groups, and not the over-
all charge of HS, permits syndecan-1 ectodomains to promote
S. aureus corneal infection by inhibiting a key arm of neutrophil
host defense.
Corneal diseases, including microbial keratitis, blind nearly 9
million people worldwide and are the second leading cause of
blindness after cataracts (1). By one estimate, the annual inci-
dence of microbial keratitis is 500,000 patients worldwide
and 30,000 patients in the United States alone (2). In addition to
being a major cause of blindness, microbial keratitis is also
associated with significant ocular morbidity, such as scarring
and reduced visual acuity (3, 4). The major bacterial pathogens
that cause keratitis are Staphylococcus aureus, Pseudomonas
aeruginosa, and Streptococcus pneumoniae (5–7). One of the
major challenges in ocular surface biology remains the ability to
define how pathogens interact with host components and mod-
ulate or co-opt their activities to promote their survival in the
corneal environment.
Many microbial pathogens, including viruses, bacteria, and
parasites, are thought to exploit the heparan sulfate (HS)2 moi-
ety of HS proteoglycans (HSPGs) to infect host cells and to
evade immune mechanisms (8, 9). HSPGs are expressed ubiq-
uitously on the cell surface and in the extracellular matrix.
HSPGs are comprised of one or several HS chains attached
covalently to specific core proteins (10). HS binds to and regu-
lates many molecules that have been implicated in the host
defense against infectious agents, including cytokines, chemo-
kines, and cationic antimicrobial factors (8, 9).
HS chains are unbranched polysaccharides comprised of
repeating disaccharide units of hexuronic acid, either glucu-
ronic (GlcA) or iduronic acid (IdoA), alternating with an
unsubstituted or N-substituted glucosamine on which the sub-
stituents are either acetate or sulfate (11–13). In HSPG biosyn-
thesis, a non-sulfated HS precursor is polymerized on specific
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serine residues of HSPG core proteins and then extensively
modified by N-deacetylase/N-sulfotransferases, C5 epimerase,
2-O-sulfotransferase (2OST), 6OSTs, and 3OSTs in the Golgi.
Unique sulfation patterns of HS are thought to dictate how
HSPGs bind to molecules and regulate biological processes,
including HS interactions with infectious agents. For example,
envelope glycoproteins E1 and E2 of hepatitis C virus require
and N- and 6-O-sulfate groups for efficient interaction with HS
(14), whereas OmcB of Chlamydia trachomatis binds to 6-O-
sulfated HS domains (15). These observations suggest that
microbes target specific HS modifications to promote their
pathogenesis, but whether GAG modifications are indeed
important in vivo has yet to be determined. In fact, our knowl-
edge of the role of HSPGs in infections is mostly derived from
cell-based experiments performed in vitro, and their physiolog-
ical significance, relevance, and function in infectious diseases
remain largely speculative.
A growing body of evidence suggests that bacterial patho-
gens subvert syndecan-1 shedding to promote their pathogen-
esis in various tissues. Syndecan-1 is the predominant HSPG of
epithelial cells, a cell type that most bacteria first encounter
during their pathogenesis (8). S. aureus (16), P. aeruginosa (17),
and S. pneumoniae (18) induce the shedding of syndecan-1
ectodomains from the cell surface through specific virulence
factors in cultured epithelial cells. Moreover, in mice, synde-
can-1 ablation is a gain of function of mutation where the syn-
decan-1 null (Sdc1/) mice are significantly protected from
P. aeruginosa (19) and S. aureus (20) lung infection, and
S. aureus corneal infection (21) compared with wild type (Wt)
mice, suggesting that syndecan-1 shedding promotes bacterial
pathogenesis. Indeed, inhibition of shedding reduces bacterial
virulence, whereas administration of purified syndecan-1 ecto-
domains or HS, but not other glycosaminoglycans or synde-
can-1 core protein devoid of HS, enhances bacterial virulence in
mouse models of infection (19, 21). These results indicate that
syndecan-1 ectodomains promote bacterial pathogenesis in an
HS-dependent manner, but precisely how this is accomplished
is incompletely understood.
Here, we examined how HS chains of syndecan-1 ectodo-
mains enhance S. aureus virulence in injured corneal tissues.
Our results surprisingly showed that 2-O-sulfated domains in
syndecan-1 HS promote S. aureus corneal infection. Our study
also showed that the antimicrobial peptide CRAMP secreted by
degranulated neutrophils selectively kills S. aureus, and 2-O-
sulfate motifs in syndecan-1 HS potently and specifically inhibit
the staphylocidal activity of CRAMP. These results reveal a new
pathogenic role for discrete domains in syndecan-1 HS in
infection.
Experimental Procedures
Materials—281-2 rat anti-mouse syndecan-1 ectodomain
and Ky8.2 rat anti-mouse syndecan-4 monoclonal antibodies
were purchased from BD Biosciences (San Jose, CA). Rabbit
anti-mouse myeloperoxidase (L607) was from Cell Signaling
(Danvers, MA) and goat anti-lactoferrin (C-15) and mouse anti-
CRAMP (G-1) antibodies were from Santa Cruz Biotechnology
(Dallas, TX). Mouse IgG was from Equitech Bio (Kerrville,
TX). S. aureus BioParticles Opsonizing Reagent, Live/Dead
BacLight Bacterial Viability Kit, Alexa Fluor 488 and 594 Anti-
body Labeling Kits were obtained from Invitrogen (Carlsbad,
CA). Chondroitin sulfate A (CS), formyl-norleucine-leucine-
phenylalanine peptide (fNLP), and cytochalasin D were from
Sigma. CRAMP peptide was synthesized at institutional core
programs or obtained from Anaspec (Fremont, CA). Percoll
was from GE Healthcare Life Sciences (Pittsburgh, PA) and
protein A-agarose and protein G-agarose beads were from
Pierce. Syndecan-1 ectodomains were purified from the condi-
tioned medium of normal mammary gland epithelial cells as
described previously (21), whereas syndecan-4 ectodomains
were partially purified from the conditioned medium by DEAE
chromatography and sequential absorption to anti-syndecan-2
and -3 and anti-syndecan-1 affinity resins to immunodeplete
other syndecans. The partially purified syndecan-4 preparation
was determined to contain no syndecan-1, -2, and -3 and glypi-
can-1 and -3 by dot immunoblotting. Porcine mucosal HS and
heparin, and N-desulfated, 2-O-desulfated and 6-O-desulfated
heparin were from Neoparin (Alameda, CA). Heparosan was
purified from E. coli K5 and chemoenzymatically N-sulfated or
N- and 2-O-sulfated as described (22). Briefly, N-sulfated hepa-
rosan was synthesized by incubating chemically deacetylated
heparosan with N-sulfotransferase and the sulfate donor
3-phosphoadenosine 5-phosphosulfate (PAPS), whereas N-
and 2-O-sulfated heparosan was made by incubating N-sulfated
heparosan with recombinant 2-O-sulfotransferase and PAPS.
Disaccharide composition analysis revealed that 95% of the
disaccharides in N-sulfated heparosan are comprised of -GlcA-
GlcNS- units, whereas N- and 2-O-sulfated heparosan is com-
posed of about 20% of -GlcA2S-GlcNS- and 80% of -GlcA-
GlcNS- disaccharide units. All other materials were purchased
from Sigma, Thermo Fisher Scientific (Waltham, MA), or VWR
(Westchester, PA).
Mice—Except for experiments comparing the response of
Wt, Sdc1/ and Sdc4/ mice on the C57BL/6J background
to S. aureus corneal infection (Fig. 1B), mice on the BALB/c
background were used in all experiments since BALB/c mice
are considered to be more susceptible to S. aureus keratitis
compared with BL/6 mice (23). Unchallenged Sdc1/ mice on
both the BALB/c and C57BL/6J backgrounds and unchallenged
Sdc4/ mice on the C57BL/6J background are healthy with
normal growth, reproduction, tissue morphology, complete
blood cell counts, and serum chemistry parameters (24 –26).
Both female and male Sdc1/, Sdc4/, and Wt mice were
used at an age of 8 –10 weeks. Mice were maintained in
microisolator cages under specific pathogen-free conditions in
a 12 h light/dark cycle and fed a basal rodent chow ad libitum.
All animal experiments were approved by the Institutional Ani-
mal Care and Use Committee of Children’s Hospital, and com-
plied with federal guidelines for research with experimental
animals.
Mouse Model of S. aureus Corneal Infection—S. aureus
strains 8325– 4 (16), P1 (27), USA300 (28), and Woods (29)
were from our culture collection. S. aureus strains were grown
to late log growth phase in tryptic soy broth (TSB), and the
bacterial concentration was approximated by turbidity mea-
surement at 600 nm. After washing, the concentration was
adjusted to 5  108 cfu/5 l. The exact bacterial concentra-
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tion in the inoculum was determined by plating out serial dilu-
tions onto TSB agar plates immediately after preparation. A
single vertical scratch was made with a 29-gauge needle in one
of the corneas of each anesthetized mouse without penetrating
beyond the superficial stroma. The other eye served as an unin-
jured control. A 5 l suspension of S. aureus was applied topi-
cally to injured or uninjured corneas, and test reagents were
administered topically at the indicated times. The dose of test
compounds was selected on preliminary titration experiments.
At 7–10 h post-infection, mice were euthanized and the bacte-
rial burden in isolated corneas was determined. Isolated cor-
neas were homogenized in TSB containing 0.1% (v/v) Triton
X-100 and serial dilutions of homogenates were plated onto
TSB agar plates.
S. aureus Killing by Neutrophils, Degranulated Neutrophil
Extracts, and CRAMP—Neutrophils were isolated from bone
marrows by Percoll gradient density centrifugation as de-
scribed previously (21). Briefly, isolated femurs and tibias were
cleaned and flushed with Hank’s Balanced Salt Solution (HBSS)
containing 10 mM HEPES, pH 7.4 (HBSS/HEPES). Bone mar-
row cells were centrifuged at 300  g for 10 min, resuspended in
45% Percoll solution, layered on top of a 62 and 81% Percoll
gradient solution, and centrifuged at 1500  g for 30 min. The
neutrophil layer between 62 and 81% Percoll was collected,
washed, resuspended in HBSS/HEPES, and counted. Neutro-
phils were incubated with pre-opsonized S. aureus Woods
strain in HBSS/HEPES containing 5% mouse serum for 2 h at
37 °C. Bacterial killing was enumerated by incubating test sam-
ples with 0.1% Triton X-100 in HBSS/HEPES for 30 min and
plating serial dilutions onto TSB agar plates. To prepare
degranulated neutrophil extracts, isolated neutrophils were
stimulated with 1 M fNLP for 1 h at 37 °C, and the superna-
tants were collected by centrifugation at 300  g for 5 min.
S. aureus killing by fNLP-stimulated neutrophils supernatants
or synthetic CRAMP was determined by incubating S. aureus
with supernatants or CRAMP peptide at the indicated doses for
2 h at 37 °C and plating serial dilutions of the test samples onto
TSB agar plates.
Histology—Eyes were enucleated from uninfected Wt or
infected Wt and Sdc1/ mice at 7 h post-infection, fixed in 4%
paraformaldehyde/PBS for 4 h at room temperature, embedded
in paraffin, and sectioned horizontally. Eye sections (5 m)
were stained with Gram solution or immunostained with
281–2 anti-mouse syndecan-1 or Ky8.2 anti-mouse syndecan-4
monoclonal antibodies directly conjugated to Alexa 594 or 488.
Stained tissue sections were visualized with a Zeiss Axiovert 40
CFL microscope and pictures were taken with the AxioCam
MRm high resolution camera. Adobe Photoshop CS6 was used
to process the acquired images.
Statistical Analyses—All data are expressed as mean plus or
minus S.E. Differences between experimental and respective
control groups were examined by Student’s t test, and p values
less than 0.05 were considered statistically significant.
Results
Corneal Epithelial Syndecan-1 Specifically Promotes S.
aureus Corneal Infection in an HS-dependent Manner—We ini-
tially examined the expression of syndecans in the cornea.
Uninfected Wt corneas showed strong expression of synde-
can-1 in the epithelium and weak expression in the endothe-
lium (Fig. 1A). Syndecan-4 was expressed in a similar pattern in
the corneal epithelium and endothelium, albeit at a lower level
than that of syndecan-1 (Fig. 1A). Syndecan-2 was weakly
expressed by keratocytes in the corneal stroma and syndecan-3
expression was not detected (data not shown). Based on these
results, we examined whether syndecan-1 functions specifically
in bacterial keratitis by comparing the response of Wt, Sdc1/,
and Sdc4/ mice to S. aureus corneal infection. Mouse cor-
neas were injured with a single vertical scratch using a 29-gauge
needle without penetrating beyond the superficial stroma and
infected topically with 5  108 cfu of S. aureus strain 8325– 4.
The corneal bacterial burden was quantified by plating out
serial dilutions of infected corneal homogenates. The infectious
burden was significantly reduced by over 10-fold in Sdc1/
corneas compared with those of Wt and Sdc4/ corneas, but
similar between Wt and Sdc4/ corneas (Fig. 1B), indicating
that ablation of syndecan-1 enables mice to specifically resist
S. aureus corneal infection.
We next examined if the protection from S. aureus infection
by syndecan-1 ablation is restricted to the 8325– 4 strain by
comparing the response of Wt and Sdc1/ corneas to infec-
tion by 8325– 4, P1 (clinical blood isolate), and USA300
(MRSA) strains. Although there were differences in the viru-
lence of each bacterial strain, Sdc1/ corneas were signifi-
cantly protected from infection by all 3 strains tested compared
with Wt corneas (Fig. 1C). Furthermore, reinforcing the pre-
vailing view that injured areas are exclusively infected in the
model of scarified corneal infection, Gram staining showed an
intense accumulation of Gram-positive S. aureus at sites where
the epithelium was scratched in Wt corneas, but not in Sdc1/
corneas (Fig. 1D). Thus, despite observations suggesting that
ablation of syndecan-1 delays wound healing in the cornea
and skin (30), and that impairment of wound healing is a
major risk factor for infection, these data suggest that synde-
can-1 both specifically and prominently promotes S. aureus
corneal infection.
Next we examined how syndecan-1 specifically enhances
S. aureus virulence and if certain structural components of syn-
decan-1 HS are important by comparing the effects of purified
syndecan-1 ectodomains, HS, CS, syndecan-1 core protein
devoid of both HS and CS chains, and partially purified synde-
can-4 ectodomains devoid of other syndecans including synde-
can-1. Because syndecan-1 shedding is maximal at 3 h after
S. aureus corneal infection (21), we administered purified ect-
odomains and related compounds at 3 h post-infection and
quantified the corneal bacterial burden 7 h later. Both purified
ectodomain and HS significantly increased the bacterial burden
in Sdc1/ corneas by 4- and 3-fold, respectively, whereas CS
and core protein did not (Fig. 2A). Purified syndecan-1 ectodo-
main and HS also similarly enhanced S. aureus virulence in
Sdc1/ corneas in a dose-dependent manner (Fig. 2B). Incu-
bation of bacteria with purified ectodomain or HS had no effect
on bacterial growth in vitro (not shown). Interestingly, partially
purified syndecan-4 ectodomains lacking syndecan-1 also sig-
nificantly increased the corneal bacterial load (Fig. 2A), indicat-
ing that other HSPGs also possess critical HS motifs that
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enhance S. aureus corneal virulence. More importantly, these
data suggest that syndecan-1 functions specifically in S. aureus
corneal infection because it is shed specifically by S. aureus
infection.
2-O-Sulfated Domains in Syndecan-1 HS Promote S. aureus
Corneal Infection—We next examined if a specific sulfate mod-
ification is important for HS’s ability to enhance S. aureus vir-
ulence in the cornea. Structures of disaccharide repeating units
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FIGURE 1. Syndecan-1 is the predominant HSPG in the mouse corneal epithelium and Sdc1/ mice specifically resist S. aureus corneal infection
compared with Wt mice. A, eye sections (5 m) of uninfected Wt mice were immunostained with 5 g/ml 281-2 anti-mouse syndecan-1 ectodomain or 5
g/ml Ky8.2 anti-mouse syndecan-4 ectodomain antibodies directly conjugated to Alexa 594 or 488 (original magnification, x200). B, scarified corneas of Wt,
Sdc1/, and Sdc4/ mice on the BL/6J background were infected topically with 5  108 cfu of S. aureus strain 8325-4. The corneal bacterial burden was
quantified 7 h after infection. Data shown are mean  S.E. (n  10 in Wt, n  12 in Sdc1/, and n  14 in the Sdc4/ groups, *, p  0.05 relative to Wt, Student’s
t test). C, scarified corneas of Wt and Sdc1/ mice on the BALB/c background were infected topically with 5  108 cfu of S. aureus 8325-4, P1 or USA300, and
the corneal bacterial burden was quantified at 7 h post-infection. Data shown are mean  S.E. (8325– 4: n  8 for both Wt and Sdc1/, P1: n  14 for both Wt
and Sdc1/, and USA300: n  14 for Wt and n  12 for Sdc1/; *, p  0.05 relative corresponding Wt). D, eye sections (5 m) of Wt and Sdc1/ mice isolated












































FIGURE 2. Syndecan-1ectodomain HS specifically promotes S. aureus corneal infection in a dose-dependent manner. A, scarified corneas of Sdc1/
mice were infected topically with 5– 6  108 cfu of S. aureus 8325-4, administered vehicle (Sdc1/, control) or 200 ng of purified syndecan-1 ectodomain, HS,
CS, core protein (CP), or partially purified syndecan-4 ectodomain at 3 h after infection, and the corneal bacterial burden was quantified at 10 h after infection
(n  16 for the control group, n  10 for the syndecan-1 ectodomain, HS and syndecan-4 ectodomain groups, n  4 for the CS and CP groups; *, p  0.05 relative
to control). B, scarified Sdc1/ corneas were infected topically with 5  108 cfu of S. aureus, administered increasing doses of purified syndecan-1 ectodomain
or HS at 3 h post-infection, and the corneal bacterial burden was measured at 10 h post-infection (n  4 for 20 ng, n  6 for 85 ng, and n  10 for 200 ng groups
for both ectodomain and HS).
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of HS are shown in Fig. 3A. HS primarily exists in nature as an
extended helical structure and does not fold into tertiary struc-
tures (31). HS functions are largely specified by how it displays
its highly negatively charged sulfate and to a lesser extent also
its carboxyl motifs. For example, 2-O-sulfate groups of HS are
essential in chick limb bud development and outgrowth (32), in
triglyceride-rich lipoprotein clearance by hepatocytes (33), and
in mammary ductal branching (34) in mice. We first tested the
effects of chemically desulfated heparin compounds on
S. aureus virulence in the cornea (Fig. 3C). Similar to purified
syndecan-1 ectodomain and HS, topical administration of hep-
arin significantly increased the bacterial burden in Sdc1/
corneas compared with control Sdc1/ corneas that received
bacteria only. Administration of N- or 6-O-desulfated heparin
also similarly increased the corneal bacterial burden. On the
other hand, removal of 2-O-sulfate groups significantly inhib-
ited the ability of heparin to increase S. aureus virulence in the
cornea, suggesting that N- and 6-O-sulfation are dispensable,
whereas 2-O-sulfation is critical for this activity. These data also
suggest that the overall net charge of syndecan-1 HS is not the
sole determinant of activity in S. aureus corneal infection since
2-O-desulfated heparin has a higher net charge than N-desul-
fated heparin.
Because chemical desulfation is selective, but not specific, we
next tested the effects of heparosan and heparosan compounds
that were sulfated in vitro (Fig. 3B). Heparosan is a capsular
polysaccharide from bacteria that has a repeating disaccharide
unit of -GlcA-GlcNAc-, and is essentially identical in structure
to unmodified HS. To confirm that 2-O-sulfate groups are
important, we synthesized N-sulfated and N- and 2-O-sulfated
heparosan using a chemoenzymatic approach (22), and tested
their effects on S. aureus virulence in the cornea. We used
N-sulfated heparosan as a substrate for 2-O-sulfation be-
cause N-sulfation is necessary to efficiently sulfate heparo-
san at the 2-O-position. Topical administration of unmodi-
fied heparosan or N-sulfated heparosan had no significant
effect on the corneal bacterial burden in Sdc1/ mice,
whereas administration of N- and 2-O-sulfated heparosan
significantly increased the corneal bacterial burden by over
5-fold compared with mice that were infected with bacteria
only (Fig. 3D). Heparin or heparosan compounds had no
effect on bacterial growth in vitro. Altogether, these data
indicate that 2-O-sulfated domains in syndecan-1 HS pro-
mote S. aureus corneal infection, and suggest that they do so
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FIGURE 3. Topical administration of 2-O-sulfated heparan compounds enhances S. aureus virulence in injured corneas. A, diagram of chemical struc-
tures of repeating disaccharide units of HS. B, chemical structures of repeating disaccharide units of heparosan and derivatives. C, scarified corneas of Sdc1/
mice were infected topically with 3  108 cfu of S. aureus (Sdc1/, control), administered 200 ng of heparin (HP), N-desulfated HP (NDS-HP), 2-O-desulfated HP
(2ODS-HP), or 6-O-desulfated HP (6ODS-HP) at 3 h post-infection, and the corneal bacterial burden was quantified at 10 after infection (n  6 in all groups; *, p 
0.05 relative to control). D, scarified Sdc1/ corneas were infected topically with 3  108 cfu of S. aureus without (Sdc1/, control), administered 500 ng of
heparosan (H), N-sulfated H (NS-H), or N- and 2-O-sulfated H (NS2OS-H) at 3 h post-infection, and the corneal bacterial burden was measured at 10 h post-
infection (n  6 in all groups; *, p  0.05 relative to control). The dose of HP and H compounds was based on preliminary titration experiments.
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2-O-Sulfated Domains in Syndecan-1 HS Inhibit the Extra-
cellular Killing of S. aureus by Neutrophils—Neutrophils are
rapidly deployed to sites of infection and injury, and are indis-
pensable in the innate host defense against the majority of acute
bacterial infections, including bacterial keratitis (35, 36). Con-
sistent with these observations, immunodepletion of neutro-
phils significantly increased S. aureus virulence in Sdc1/ cor-
neas (21), indicating that neutrophils are essential to rapidly
clear S. aureus and enable Sdc1/ mice to resist S. aureus cor-
neal infection. However, neutrophils do not express syndecan-1
and do not bind to syndecan-1. Syndecan-1 also does not regu-
late neutrophil influx into corneas infected with S. aureus, and
isolated neutrophils of both Sdc1/ and Wt mice similarly kill
S. aureus (21). Moreover, Wt and Sdc1/ neutrophils are sim-
ilar in size, granularity, and pattern of GR1 staining, Sdc1/
neutrophils do not have an inherent defect in their ability to
migrate, and Sdc1/ mice contain normal numbers of circu-
lating neutrophils (25, 37). Instead, syndecan-1 ectodomains
have been shown to promote S. aureus corneal infection by
inhibiting neutrophil-mediated S. aureus killing in an HS-de-
pendent manner (21).
Thus, we next explored whether specific structural features
of syndecan-1 HS inhibit the host defense activities of neutro-
phils against S. aureus. We first examined the effects of chem-
ically desulfated heparin and chemoenzymatically sulfated
heparosan on the killing of pre-opsonized S. aureus by Wt neu-
trophils isolated from the bone marrow. Heparin significantly
inhibited S. aureus killing by neutrophils, and removal of sulfate
groups at the N- or 6-O-position had no effect on this inhibitory
activity (Fig. 4A). However, 2-O-desulfated heparin lost its
capacity to inhibit S. aureus killing by neutrophils, suggesting
that 2-O-sulfate groups are important. Consistent with these
observations, heparosan and N-sulfated heparosan only slightly
inhibited S. aureus killing by neutrophils, but the marginal dif-
ference (4%) did not reach significance (Fig. 4B). In contrast,
N- and 2-O-sulfated heparosan significantly inhibited the kill-
ing of S. aureus by neutrophils (Fig. 4B). At the doses tested, the
heparin and heparosan compounds did not affect the viability
of isolated neutrophils. These findings suggest that 2-O-sul-
fated domains in syndecan-1 HS promote S. aureus corneal
infection by inhibiting bacterial killing by neutrophils.
Neutrophils can kill bacteria by extracellular or intracellular
phagocytic mechanisms. Most of the antimicrobial activity of
neutrophils are thought to occur within intracellular phago-
somes, but extracellular killing mechanisms involving antimi-
crobial factors secreted by neutrophil degranulation or released
and embedded in neutrophil extracellular traps also comprise
an important arm of host defense against infections (36). To
determine how 2-O-sulfated domains in syndecan-1 HS inhibit
S. aureus killing by neutrophils, we first examined the effects of
HS on the rate of phagocytic killing. Wt neutrophils were incu-
bated with pre-opsonized S. aureus in the absence or presence
of HS for 15, 30, 60, or 90 min, incubated with gentamycin to kill
extracellular bacteria, and the intracellular bacterial load was
determined. The number of live intracellular bacteria was sim-
ilar between the neutrophils incubated with bacteria only and
with bacteria and HS at all times examined (Fig. 5A), indicating
that HS does not inhibit phagocytic killing mechanisms of neu-
trophils. In fact, intracellular killing was slightly inhibited by HS
at 90 min postincubation, although the difference did not reach
significance (Fig. 5A).
Next, we examined the effects of purified syndecan-1 ectodo-
main and related compounds on the extracellular killing of
S. aureus by neutrophils. Neutrophils were pre-treated with
cytochalasin D to inhibit phagocytosis and incubated with
S. aureus in the absence or presence of purified syndecan-1 ecto-
domain, HS, CS, heparosan, or N- and 2-O-sulfated heparosan.
Purified ectodomain, HS, and N- and 2-O-sulfated heparosan
significantly inhibited the extracellular killing of S. aureus by
neutrophils, whereas CS and heparosan did not (Fig. 5B).
Together with the data from the phagocytic killing assay, these
findings suggest that 2-O-sulfated domains in syndecan-1 HS
promote S. aureus corneal infection by inhibiting antibacterial
factors secreted from neutrophils.
We further explored this hypothesis by examining the effects
of purified syndecan-1 ectodomain and heparan compounds on
the antibacterial activity of degranulated contents collected
from neutrophils stimulated with the formylated tripeptide,
formyl-norleucine-leucine-phenylalanine (fNLP). Neutrophils
express heterogeneous granules and vesicles that contain vari-
ous peptides and proteins with antimicrobial activity (38).






























































FIGURE 4. 2-O-sulfated domains in HS inhibit the staphylocidal activity of neutrophils. A, Wt neutrophils (5  105) were incubated with 2  103 cfu of
pre-opsonized S. aureus in the absence (control) or presence of 3 g/ml HP, NDS-HP, 2ODS-HP, or 6ODS-HP for 2 h at 37 °C. Percent bacterial killing was
enumerated by plating serial dilutions of detergent lysates onto TSB agar plates (n  4, *, p  0.05 relative to control). B, Wt neutrophils (5  105) were
incubated with 2  103 cfu of pre-opsonized S. aureus in the absence (control) or presence of 10 g/ml H, NS-H, or NS2OS-H for 2 h at 37 °C and bacterial killing
was determined (n  8, *, p  0.05 relative to control). The dose of HP and H compounds was selected on preliminary titration experiments with HP or NS2OS-H.
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neutrophil stimulation by both biological and chemical re-
agents, including microbial products (e.g. formylated peptides,
glycolipids), cytokines, and chemokines, and phorbol esters. In
general, granules formed during the late stages of neutrophil
differentiation are more readily mobilized than granules
formed during the early stages of differentiation (39). Stimula-
tion by fNLP released both specific (lactoferrin, CRAMP) and
azurophilic (myeloperoxidase) granule contents (not shown).
Moreover, we found that fNLP-stimulated neutrophil extracts
possess potent staphylocidal activity, which was significantly
inhibited by purified ectodomain and 2-O-sulfated heparan
compounds (HS, and N- and 2-O-sulfated heparosan), but not
by those lacking 2-O-sulfate motifs (CS or unmodified heparo-
san) (Fig. 5C). Together, these data indicate that 2-O-sulfated
domains in syndecan-1 HS inhibit S. aureus killing by degranu-
lated neutrophil antimicrobial factors, and suggest that synde-
can-1 HS inhibits this particular arm of extracellular killing
mechanism to enhance S. aureus virulence in corneal tissues.
Syndecan-1 HS Inhibit the Killing of S. aureus by CRAMP
through Its 2-O-Sulfated Domains—Next, to identify the de-
granulated neutrophil factor inhibited by syndecan-1 HS,
we first examined the effects of immunodepleting several
antimicrobial factors with anti-staphylococcal activity from
fNLP-stimulated neutrophil supernatants on S. aureus killing.
Immunoprecipitation with nonspecific mouse IgG or immu-
nodepletion of lactoferrin or myeloperoxidase did not inhibit
S. aureus killing by degranulated neutrophil supernatants (Fig.
6A). On the other hand, immunodepletion of the cationic anti-
microbial peptide CRAMP significantly inhibited the staphylo-
cidal activity of degranulated neutrophil supernatants (Fig. 6A),
suggesting that syndecan-1 HS inhibits CRAMP to inhibit
S. aureus killing by neutrophils.
CRAMP kills S. aureus (40) and S. aureus killing by LL-37,
the human homologue of CRAMP, is inhibited by HS (41, 42).
Consistent with these reports, we found that incubation with
synthetic CRAMP for 2 h kills over 90% of S. aureus (Fig. 6B).
Importantly, purified syndecan-1 ectodomain, HS, and N- and
2-O-sulfated heparosan, but not unmodified heparosan with-
out 2-O-sulfate groups, abolished or significantly inhibited
S. aureus killing by CRAMP (Fig. 6B). These findings were also
confirmed by a live/dead staining assay where most S. aureus
cells incubated with CRAMP only or CRAMP and heparosan
were dead (red), whereas the majority of those incubated with
CRAMP and ectodomain, HS, or N- and 2-O-sulfated heparo-
san were alive (green) (Fig. 6C).
Together with data from the immunodepletion experiments,
these data suggest that syndecan-1 HS specifically inhibits










































































FIGURE 5. 2-O-sulfated domains in syndecan-1 HS inhibit extracellular killing mechanisms of neutrophils. A, Wt neutrophils (5  105) were incubated
with pre-opsonized S. aureus for 15, 30, 60, or 90 min in the absence or presence of 3 g/ml HS, washed, incubated with 100 g/ml gentamycin for 30 min to
kill extracellular bacteria, washed, treated with TSB containing 0.1% (v/v) Triton X-100, and detergent lysates were plated out to determine the rate of
phagocytic killing (mean  S.E., n  5). B, Wt neutrophils (5  105) were pre-treated with 10 g/ml cytochalasin D, incubated with S. aureus (2  103 cfu) in the
presence of cytochalasin D without or with 1 g/ml purified ectodomain, 3 g/ml HS or CS, or 10 g/ml H or NS2OS-H for 2 h at 37 °C, and bacterial killing was
determined (n  22 for the cytochalasin D group, n  11 for the 	Ecto group, n  16 for the 	HS group, n  4 for 	CS and 	H groups, and n  5 for the
	NS2OS-H group; *, p  0.05 relative to the cytochalasin D group). C, supernatants from neutrophils stimulated with 1 M fNLP for 1 h were incubated with
S. aureus (1.5  103 cfu) in the absence (fNLP sup) or presence of 1 g/ml ectodomain, 3 g/ml HS or CS, or 10 g/ml H or NS2OS-H for 2 h at 37 °C, and bacterial
killing was determined (n  5 in all groups; *, p  0.05 relative to the fNLP sup group).
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S. aureus corneal infection. However, why syndecan-1 HS tar-
gets CRAMP and not other cationic antimicrobial peptides
with anti-staphylococcal activity is not clear. Because most
antimicrobial peptides and proteins kill S. aureus at relatively
high doses, perhaps the concentration of other staphylocidal
factors released from degranulated neutrophils by fNLP stimu-
lation did not reach the effective dose. Also, since mouse neu-
trophils do not express defensins (43), which are inhibited by
syndecan-1 HS (19), it is quite possible that syndecan-1 ectodo-
mains may inhibit multiple cationic antimicrobial peptides in
clinical S. aureus keratitis. Regardless, our data clearly show
that 2-O-sulfated domains in syndecan-1 HS specifically and
potently inhibit S. aureus killing by CRAMP, degranulated neu-
trophil extracts and intact neutrophils, and promote S. aureus
corneal infection in vivo.
Discussion
We report here that syndecan-1 is abundantly and selectively
expressed in the corneal epithelium, and that HS chains of syn-
decan-1 promote S. aureus corneal infection in mice. While cell
surface HSPGs are widely thought to promote infection by
serving as attachment sites for pathogens, syndecan-1 does not
bind directly to S. aureus and does not facilitate S. aureus adhe-
sion to cultured corneal epithelial cells (21). Instead, synde-
can-1 is shed from the cell surface during S. aureus corneal
infection and the shed ectodomain enhances S. aureus viru-
lence in corneal tissues. Our results here indicate that HS
chains of syndecan-1 ectodomain promote pathogenesis by
impeding bacterial clearance by neutrophils. We found that
syndecan-1 ectodomain does not inhibit phagocytic killing of
S. aureus by neutrophils, but that it significantly inhibits
S. aureus killing by antimicrobial factors secreted by degranu-
lated neutrophils. Our studies also showed that the antimicro-
bial peptide CRAMP is the primary target of syndecan-1 ecto-
domains in degranulated neutrophil extracts. Furthermore, our
study showed that 2-O-sulfate groups in HS are essential for all
of these pro-pathogenic activities of syndecan-1 ectodomain.
Together, these observations suggest a new function of synde-
can-1 in microbial pathogenesis where 2-O-sulfate motifs in its
HS chains promote S. aureus corneal infection by inhibiting
S. aureus killing by neutrophil CRAMP.
Our results showing that Sdc1/ mice, but not Sdc4/
mice, are significantly protected against S. aureus corneal infec-
tion suggest that syndecan-1 functions specifically in this infec-
tious disease, despite similar cellular distribution patterns of
syndecan-1 and -4 in the corneal epithelium. How this is














































































CRAMP + NS2OS-HCRAMP + HCRAMP + HS
CRAMP + EctoCRAMP
FIGURE 6. Neutrophil extracellular killing of S. aureus is mediated by CRAMP, and syndecan-1 ectodomain and 2-O-sulfated heparan compounds
inhibit killing of S. aureus by CRAMP. A, supernatants from Wt neutrophils stimulated with fNLP were incubated with S. aureus (1.5  103 cfu) or were
immunoprecipitated with mouse IgG, anti-CRAMP, anti-MPO, or anti-lactoferrin antibodies and then incubated with S. aureus for 2 h at 37 °C, and % bacterial
killing was determined (n  5 in all groups, *, p  0.05 compared with the fNLP sup group). B, CRAMP (10 g/ml) was pre-incubated with vehicle or 10 g/ml
purified ectodomain, HS, H, or NS2OS-H for 15 min and then incubated with S. aureus (103 cfu) for 2 h at 37 °C, and % bacterial killing was determined (n  6 in
all groups; *, p  0.05 compared with the CRAMP only group). C, S. aureus incubated with vehicle, CRAMP, or CRAMP and ectodomain, HS, H, or NS2OS-H were
stained for live and dead bacteria.
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that both purified syndecan-1 ectodomains and partially puri-
fied syndecan-4 ectodomains devoid of other syndecans are
capable of enhancing S. aureus corneal virulence. However,
syndecan-1 is expressed at a higher level than that of synde-
can-4 in the corneal epithelium, so the abundance of synde-
can-1 may overwhelm the potential effects of syndecan-4 in
S. aureus corneal infection. Furthermore, -toxin is a major
virulence factor for S. aureus corneal infection (44, 45), and we
previously found that -toxin stimulates the shedding of syn-
decan-1, but not syndecan-4 ectodomains in cell culture-based
assays (16), suggesting that the specific functions of syndecan-1
in corneal tissues are also controlled by its susceptibility to
-toxin-induced ectodomain shedding.
Alternatively, because our results suggest that discrete HS
domains enhance S. aureus virulence in the cornea, syndecan-1
HS may contain unique structural features that enable it to
function specifically in S. aureus corneal infection. However,
opposing this idea are the findings that only minor structural
and functional differences are found in HS chains of syndecan-1
and -4 in mouse mammary gland epithelial cells (46) and of
syndecan-4 and glypicans in rat embryonic fibroblasts (47), sug-
gesting that structural features of HS chains are cell type spe-
cific and not core protein specific. Taken together, these obser-
vations suggest that the prominent functions of syndecan-1 in
S. aureus corneal infection are considered to be a reflection of
its abundant expression and selective shedding by S. aureus
-toxin.
Our results also showed that syndecan-1 HS does not affect
intracellular phagocytic killing of S. aureus by neutrophils, but
instead inhibits an extracellular killing mechanism of S. aureus
by CRAMP secreted upon neutrophil degranulation. Because
S. aureus possesses multiple mechanisms to evade intracellular
phagosomal killing (48 –50), perhaps S. aureus subverts synde-
can-1 only to protect itself from extracellular killing by
degranulated antimicrobial factors. CRAMP belongs to the
cathelicidin family of antimicrobial peptides, which includes
human LL-37, porcine PR-39, and bovine bactenecins, among
others (51). The importance of the cathelicidins in host defense
is quite clear from both animal and cell-based infection studies.
For example, LL-37 kills a wide variety of microbial pathogens,
including viruses, bacteria and fungi, and is chemotactic for
leukocytes (51). Knock-out mice lacking the CRAMP gene
(Cnlp/) show increased morbidity or mortality in group A
Streptococcus skin infection (52), Klebsiella pneumoniae lung
infection (53), P. aeruginosa corneal infection (54), E. coli uri-
nary tract infection (55), and Citrobacter rodentium intestinal
infection (56). These observations suggest that despite the fact
that antimicrobial peptide functions are considered largely
redundant, the cathelicidins appear to be essential host defense
factors in certain infectious diseases. Based on these observa-
tions, we propose that subversion of syndecan-1 HS to inhibit
neutrophil CRAMP may be a critical virulence activity of
S. aureus in the cornea.
It is important to note that CRAMP is not only expressed by
neutrophils, but also by macrophages and epithelial cells (51),
suggesting that syndecan-1 HS may also inhibit CRAMP pro-
duced by other cell types in S. aureus corneal infection. How-
ever, the observation that CRAMP is not expressed in injured
but uninfected mouse corneas (57) suggest that epithelial cell-
derived CRAMP is not targeted for inhibition by syndecan-1,
although epithelial cells are thought to make antimicrobial
peptides on request. More importantly, we previously found
that neutrophil depletion significantly enhances S. aureus
virulence in the Sdc1/ cornea (21), which provides additional
evidence that neutrophil-derived, and not epithelial cell-de-
rived CRAMP is important.
One of the major findings of our study was that 2-O-sulfated
groups are essential for the ability of syndecan-1 HS to inhibit
CRAMP- and neutrophil-mediated S. aureus killing, and to
promote S. aureus corneal infection in mice. These observa-
tions were surprising because many HS activities are thought to
depend more on the overall organization of HS domains and on
the overall net charge of the glycosaminoglycan than on specific
modifications (13). However, the structural basis of how HS
regulates biological molecules and their processes is still being
worked out. What is known for 2-O-sulfation is that it is essen-
tial for normal development since mice deficient in 2-O-sulfo-
transferase die few days after birth due to renal agenesis and
CNS and skeletal abnormalities (58). Regulation of several
growth factor activities by HS, such as FGF signaling and Wnt
signaling (59, 60), and uptake of plasma lipoproteins by hepa-
tocytes (33) have also been shown to be dependent on the pres-
ence of 2-O-sulfated uronic acids. However, how 2-O-sulfate
groups in HS mediate the inhibition of neutrophil CRAMP-
mediated host defense and enhance S. aureus virulence in the
cornea have yet to be elucidated. Because HS binds to antimi-
crobial peptides and inhibit their antibacterial activity by inter-
fering with peptide binding to target bacterial cells (19), synde-
can-1 HS is also expected to inhibit CRAMP in a similar
manner. A particular binding site in CRAMP may directly bind
to 2-O-sulfated uronic acids in syndecan-1 HS or bind to a
conformation of syndecan-1 HS that is dictated by 2-O-sulfated
motifs. In fact, spacing of cationic amino acids is important for
the anti-bacterial activity of LL-37 (61), suggesting that similar
spacing of cationic residues in CRAMP may allow this peptide
to avidly bind to 2-O-sulfate motifs in syndecan-1 HS.
Furthermore, the antibacterial activity of LL-37 is dependent
on the extent of amphipathic -helicity (62). In water, however,
LL-37 exhibits a disordered structure consistent with the fact
that the energy provided by the hydrogen bonds are not suffi-
cient to overcome the entropic energy associated with folding
in short polypeptides, suggesting that the -helical content of
cathelicidins increases when mobilized to kill pathogens. Con-
sidering the fact that hydrogen bonds of short peptide -helices
are readily broken by water, perhaps binding of highly anionic
molecules like syndecan-1 HS, which would accompany water,
may disrupt the -helicity of CRAMP and hence its anti-staph-
ylococcal activity. Alternatively or concurrently, syndecan-1
HS binding may prevent CRAMP oligomerization, which is
considered important for cathelicidins to form toroidal pores in
bacterial membranes (62). Additional studies are required to
precisely determine how 2-O-sulfated domains in syndecan-1
HS inhibit CRAMP activity.
Another interesting finding of this study was that 2-O-sul-
fated heparosan inhibits CRAMP- and neutrophil-mediated
S. aureus killing, and enhances S. aureus virulence in mouse
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corneas. HS 2-O-sulfation can occur on both IdoA and GlcA,
but is mostly found on IdoA in native HS and heparin due pri-
marily to a higher affinity of 2-O-sulfotransferase for IdoA over
GlcA (63). However, heparosan only contains GlcA, suggesting
an intriguing possibility where 2-O-sulfated GlcA (GlcA2S)-
containing domains in syndecan-1 HS mediate its pro-patho-
genic activities in S. aureus corneal infection. IdoA can assume
both a 4C1 chair and 2S0 skew boat forms as these have nearly
identical energy conformations (64), allowing IdoA to bind to
HS-binding ligands in either conformation. This conforma-
tional flexibility of IdoA is thought to be important for the abil-
ity of heparin and HS to interact with many proteins. In con-
trast, GlcA prefers a 4C1 conformation, giving a relatively rigid
structural unit in HS and heparin and potentially mediate spe-
cific interactions with certain HS-binding ligands (64). Thus,
syndecan-1 HS binding to CRAMP may be dictated by regions
containing GlcA2S and that this interaction mediates the highly
specific activities of syndecan-1 HS and 2-O-sulfated heparan
compounds in S. aureus corneal infection. However, our results
do not completely exclude the possibility that IdoA2S in the 4C1
chair conformation can function similarly.
In addition, although GlcA2S is a rare modification and the
content of GlcA2S in corneal syndecan-1 HS is not known, it is
worth noting that certain tissues, such as the liver (65) and brain
(66), have a higher proportion of GlcA2S, suggesting a possibil-
ity where corneal epithelial tissues may also contain higher lev-
els of this sulfate modification. Interestingly, an unusual N-un-
substituted and 3-O-sulfated glucosamine unit has been shown
to mediate the specific binding of herpes simplex virus gD pro-
tein (67), suggesting that certain pathogens may subvert rare
HS modifications in syndecan-1 for their pathogenesis.
In sum, our findings reveal a new pathogenic role for synde-
can-1 in S. aureus corneal infection where its shed ectodomain
inhibits neutrophil-mediated defense mechanisms crucial to
the clearance of S. aureus in the cornea. Although the normal
functions of syndecan-1 in the cornea remain to be elucidated,
our findings suggest a possible beneficial role of inhibiting syn-
decan-1 HS and, in particular, the activity of 2-O-sulfated HS
domains in treating S. aureus keratitis, for which new interven-
tions are needed. Furthermore, CRAMP is not only important
for host defense against S. aureus, but has also been shown to be
critical in infections caused by other major pathogens of the
ocular surface, such as P. aeruginosa (54) and S. pneumoniae
(68). These observations suggest that neutralizing syndecan-1
HS to enhance CRAMP activity may be a viable option for the
treatment of infectious keratitis caused by multiple bacterial
pathogens of the ocular surface.
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